Literature DB >> 21072510

Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.

David Groheux, Sylvie Giacchetti, Marc Espié, Domenico Rubello, Jean-luc Moretti, Elif Hindié.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21072510     DOI： 10.1007/s00259-010-1660-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  30 in total

Review 1.  Research issues affecting preoperative systemic therapy for operable breast cancer.

Authors:  Antonio C Wolff; Donald Berry; Lisa A Carey; Marco Colleoni; Mitchell Dowsett; Matthew Ellis; Judy E Garber; David Mankoff; Soonmyung Paik; Lajos Pusztai; Mary Lou Smith; JoAnne Zujewski
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

2.  Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

Authors:  Garry M McDermott; Andrew Welch; Roger T Staff; Fiona J Gilbert; Lutz Schweiger; Scott I K Semple; Tim A D Smith; Andrew W Hutcheon; Iain D Miller; Ian C Smith; Steven D Heys
Journal:  Breast Cancer Res Treat       Date:  2006-08-09       Impact factor: 4.872

3.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors:  Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal:  Lancet       Date:  2010-01-30       Impact factor: 79.321

4.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

5.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

8.  The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Authors:  Amandeep Kumar; Rakesh Kumar; Vathalaru Seenu; Sidharatha Datta Gupta; Madhavi Chawla; Arun Malhotra; Sada Nand Mehta
Journal:  Eur Radiol       Date:  2009-02-13       Impact factor: 5.315

9.  The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Authors:  M E Straver; E J Th Rutgers; S Rodenhuis; S C Linn; C E Loo; J Wesseling; N S Russell; H S A Oldenburg; N Antonini; M T F D Vrancken Peeters
Journal:  Ann Surg Oncol       Date:  2010-04-06       Impact factor: 5.344

10.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544
View more
  26 in total

1.  AI-based applications in hybrid imaging: how to build smart and truly multi-parametric decision models for radiomics.

Authors:  Isabella Castiglioni; Francesca Gallivanone; Paolo Soda; Michele Avanzo; Joseph Stancanello; Marco Aiello; Matteo Interlenghi; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-11       Impact factor: 9.236

2.  FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer.

Authors:  David Groheux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

Review 3.  ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.

Authors:  David Groheux; David Mankoff; Marc Espié; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-13       Impact factor: 9.236

4.  Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.

Authors:  Ana María García Vicente; Ángel Soriano Castrejón; Alberto León Martín; Fernanda Relea Calatayud; María Del Mar Muñoz Sánchez; Miguel Ángel Cruz Mora; Germán Andrés Jiménez Londoño; Ruth Espinosa Aunión
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-18       Impact factor: 9.236

5.  Portable, parallel 9-wavelength near-infrared spectral tomography (NIRST) system for efficient characterization of breast cancer within the clinical oncology infusion suite.

Authors:  Yan Zhao; Brian W Pogue; Steffen J Haider; Jiang Gui; Roberta M diFlorio-Alexander; Keith D Paulsen; Shudong Jiang
Journal:  Biomed Opt Express       Date:  2016-05-16       Impact factor: 3.732

6.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

7.  Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Authors:  David Groheux; Mohamed Majdoub; Florent Tixier; Catherine Cheze Le Rest; Antoine Martineau; Pascal Merlet; Marc Espié; Anne de Roquancourt; Elif Hindié; Mathieu Hatt; Dimitris Visvikis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-04       Impact factor: 9.236

8.  99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.

Authors:  David Mitchell; Carrie B Hruska; Judy C Boughey; Dietlind L Wahner-Roedler; Katie N Jones; Cindy Tortorelli; Amy Lynn Conners; Michael K O'Connor
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

9.  Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.

Authors:  B B Koolen; M J T F D Vrancken Peeters; J Wesseling; E H Lips; W V Vogel; T S Aukema; E van Werkhoven; K G A Gilhuijs; S Rodenhuis; E J Th Rutgers; R A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-16       Impact factor: 9.236

10.  Usefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.

Authors:  Hyung-Jun Im; Yu Kyeong Kim; Yong-Il Kim; Jong Jin Lee; Won Woo Lee; Sang Eun Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.